---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-25-000208"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2025-12-04T23:59:59+00:00"
generated_at: "2026-05-16T14:50:17.384318+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Denali secures $275M royalty funding from Royalty Pharma on tividenofusp alfa

## Summary
- Royalty Pharma pays $200M at close conditional on FDA accelerated approval by June 30, 2026.
- Additional $75M due upon EMA approval by Dec 31, 2029; royalty rate 9.25% on worldwide net sales.
- Royalty ceases at 3.0x multiple (2.5x if reached by Q1 2039); Denali retains full rights.
- PDUFA target date for tividenofusp alfa BLA is April 5, 2026; MPS II (Hunter syndrome) therapy.
- Denali CFO states funds advance platform and launch preparation without dilution.

## SEC filing metadata
- accession: 0001714899-25-000208
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2025-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/0001714899-25-000208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/dnli-20251204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-25-000208
- JSON: https://secwatch.observer/filing/0001714899-25-000208.json
- Plain text: https://secwatch.observer/filing/0001714899-25-000208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.